Efficacy of generic sofosbuvir with daclatasvir compared to sofosbuvir/ledipasvir in genotype 4 hepatitis C virus: A prospective comparison with historical control

Efficacy of generic sofosbuvir with daclatasvir compared to sofosbuvir/ledipasvir in genotype 4 hepatitis C virus: A prospective comparison with historical control

Abstract Background and Aim Management of genotype 4 hepatitis C virus (HCV) has shifted to interferon‐free regimens with a high sustained virological response (SVR‐12), especially with NS5B/NS5A inhibitor combinations such as sofosbuvir and ledipasvir (Sof‐Led). The guidelines have recommended the...

Cijeli opis

Bibliografski detalji
Glavni autori: Hala Joharji, Delal Alkortas, Aziza Ajlan, Mohamed Ahmed, Hamad Al‐Ashgar, Mohammed Al‐Quaiz, Dieter Broering, Mohammed Al‐Sebayel, Hussien Elsiesy, Faisal A. Alkhail, Waleed K. Al‐Hamoudi, Edward De Vol, Epi Amirah Almuhayshir, Ahmed Al‐Jedai
Format: Članak
Jezik:English
Izdano: Wiley 2023-01-01
Serija:Health Science Reports
Teme:
cost saving
direct acting antivirals
sustained virological response
viral hepatitis
Online pristup:https://doi.org/10.1002/hsr2.980

Internet

https://doi.org/10.1002/hsr2.980

Slični predmeti